Breaking News

Pfizer Bolsters Oncology Pipeline with $1.25B 3SBio Deal

Gains exclusive rights for the development, manufacturing and commercialization of 3SBio’s SSGJ-707.

Author Image

By: Charlie Sternberg

Associate Editor

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization of 3SBio’s SSGJ-707, a bispecific antibody targeting PD-1 and VEGF. This agreement further enhances Pfizer’s oncology pipeline. “We are excited to contribute our significant expertise and resources to advance rapidly the development of the SSGJ-707 program including novel combination strategies a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters